The professor of neurology at NYU Langone Grossman School of Medicine discussed her talk at AAN 2022 on neurological sequelae and follow-up in hospitalized and nonhospitalized patients with COVID-19. [WATCH TIME: 8 minutes]
WATCH TIME: 8 minutes
"What’s interesting is that 20% of people said they have some cognitive problem, but 50% tested abnormal. There’s some anosognosia. There are certain people that are like, ‘I’m fine!’ and they’re not fine. That’s a really interesting group of people."
It has been frequently reported that COVID-19 infection may result in post-acute neurological sequelae, mainly in forms of fatigue, headaches, and memory impairment; however, little is known about trajectory of recovery 12-months after hospitalization for severe COVID-19. To better understand this, a group of investigators conducted a prospective, longitudinal cohort study of patients with and without neurological complications during index hospitalization from March 2020 to May 2020.
Of the 242 included patients, 47% (n = 113) had neurological complications during index hospitalization and 53% (n = 129) had no neurological complications during hospitalization. At 12 months, 87% (197 of 227) of patients who completed all follow-up batteries had at least 1 abnormal metric. More specifically, 75% (176 of 235) had a modified Rankin Scale (mRS) score greater than 0, 64% (150 of 236) had a Barthel Index of Activities of Daily Living less than 100, and 50% (80 of 161) of patients without a prior history of dementia/cognitive abnormalities had an abnormal telephone Montreal Cognitive Assessment (t-MoCA) score. Excluding patients with pre-COVID-19 mRS scores greater than 0, 82% (107 of 130) of patients had at least 1 abnormal metric at 12 months.
Lead investigator Jennifer Frontera, MD, professor of neurology at NYU Langone’s Grossman School of Medicine, gave a talk at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, Washington discussing her experience with hospitalized and nonhospitalized patients with COVID-19 and the neurological sequelae seen at follow-up. As someone who has worked in the ICU since the inception of the pandemic, Frontera has been able to see a majority of these changes firsthand.
NeurologyLive® caught up with Frontera at AAN 2022 to discuss her presentation, along with her thoughts on the general state of post-acute sequelae-related research. She stressed the need to capture detailed data on patients with infections, their neurological abnormalities, and any additional complications they may be experiencing.